Ardent Health Slashes 2026 Profit Outlook as Surgery Volumes Drop
ARDT sits 49% above its 52-week low of $7.71.
Summary
Ardent Health cut its 2026 net income and EPS guidance, citing lower surgery and admission volumes that hurt Q2 performance. Revenue fell 1.4% year-over-year to $1.62B, though it beat the $1.59B consensus, and adjusted EBITDA of $115M also topped estimates. The company repurchased 1.4M shares for $13M and raised expected savings from its IMPACT cost program to at least $70M from $55M. This follows the CEO change in June and reaffirmed EBITDA guidance in the 8-K filed today, but the profit warning signals deeper operational headwinds. The stock closed at $10.75 on August 3, and the lowered outlook may pressure the 12-month median price target of $12.
At the time of this announcement, ARDT was trading at $11.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $7.71 to $15.48. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.